InvestSMART

Immutep Limited (ASX: IMM) - Announcements

Current share price for IMM : $0.028 0.002 (6.67%)+

ASX company news and announcements for Immutep Limited (IMM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immutep Limited (IMM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immutep Limited (IMM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immutep Limited (IMM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$41 Immutep hosts Key Opinion Leader Call 25 Jun 2019 8:25AM $0.026 $0.028 risen by 7.69%
$41 Immutep granted Australian patent for eftilagimod alpha 21 Jun 2019 8:16AM $0.026 $0.028 risen by 7.69%
$41 Immutep completes recruitment of initial NSCLC cohort 13 Jun 2019 9:56AM $0.026 $0.028 risen by 7.69%
$41 First patient dosed in INSIGHT-004 6 Jun 2019 8:29AM $0.026 $0.028 risen by 7.69%
$41 Appendix 3B 3 Jun 2019 5:47PM $0.027 $0.028 risen by 3.70%
$41 Immutep Poster Presentation at ASCO 3 Jun 2019 8:29AM $0.027 $0.028 risen by 3.70%
$41 Immutep granted European patent for eftilagimod alpha 23 May 2019 8:20AM $0.029 $0.028 fallen by 3.45%
$41 More mature positive data for TACTI-mel trial presented 17 May 2019 8:23AM $0.029 $0.028 fallen by 3.45%
$41 Immutep to present at upcoming industry conferences 10 May 2019 3:52PM $0.028 $0.028 fallen by 0%
$41 Becoming a substantial holder 8 May 2019 8:25AM $0.027 $0.028 risen by 3.70%
$41 Operational Update 30 Apr 2019 9:41AM $0.028 $0.028 fallen by 0%
$41 Appendix 4C - quarterly 24 Apr 2019 6:16PM $0.028 $0.028 fallen by 0%
$41 Webcast slides for eftilagimod alpha (IMP321) 2 Apr 2019 7:28PM $0.031 $0.028 fallen by 9.68%
$41 Webcast details for update on eftilagimod alpha (IMP321) 27 Mar 2019 6:29PM $0.033 $0.028 fallen by 15.15%
$41 Ceasing to be a substantial holder 26 Mar 2019 10:50AM $0.036 $0.028 fallen by 22.22%
$41 IMP761 Webcast Slides 25 Mar 2019 8:28PM $0.036 $0.028 fallen by 22.22%
$41 Immutep granted US patent for IMP321 22 Mar 2019 8:22AM $0.034 $0.028 fallen by 17.65%
$41 Webcast to discuss IMP761 preclinical results 19 Mar 2019 8:23AM $0.033 $0.028 fallen by 15.15%
$41 IMP761 results presented at ECCO conference 8 Mar 2019 8:21AM $0.034 $0.028 fallen by 17.65%
$41 Immutep receives A$872,351 R&D Tax Incentive 7 Mar 2019 7:21PM $0.034 $0.028 fallen by 17.65%
$41 Immutep doses First Patient in TACTI-002 Phase II Trial 6 Mar 2019 6:00PM $0.035 $0.028 fallen by 20%
$41 TACTI-mel data presented at World Immunotherapy Congress 6 Mar 2019 8:20AM $0.034 $0.028 fallen by 17.65%
$41 Immutep to present at Oppenheimer Healthcare Conference 4 Mar 2019 6:59PM $0.032 $0.028 fallen by 12.50%
$41 Half Year Accounts 27 Feb 2019 4:58PM $0.030 $0.028 fallen by 6.67%
$41 Immutep to present at upcoming industry conferences 26 Feb 2019 1:29PM $0.030 $0.028 fallen by 6.67%

676 - 700 of 786 results

Page 28 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.